News and Events

GangaGen Secures additional US$7.9 Million from CARB-X for Pre-clinical Development of Novel Klebicins Targeting Nosocomial Pneumonia caused by Multidrug-resistant Klebsiella pneumoniae

December 20, 2024

GangaGen Achieves Initial CARB-X Milestone for Klebicin Program Targeting Pneumonia caused by Multidrug-resistant Klebsiella pneumoniae Bacteria and Secures US$2.1 Million for Lead Optimization

August 11, 2023

Exciting Sports Day at GangaGen

July 20, 2023

GangaGen Celebrates Employee Achievements

June 1, 2023

CARB-X is Funding GangaGen Biotechnologies to Develop a New Drug to Treat Pneumonia Caused by Multidrug-resistant Klebsiella pneumoniae Bacteria

October 4, 2020